NCT02779257 2022-03-04Pasireotide Treatment for Neuroendocrine TumorUniversity of Maryland, BaltimorePhase 4 Withdrawn
NCT03053284 2021-05-14Pasireotide in Hyperinsulinemic HypoglycemiaMontefiore Medical CenterPhase 2 Withdrawn